FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2330367837> ?p ?o ?g. }

• W2330367837 endingPage "53" @default.
• W2330367837 startingPage "47" @default.
• W2330367837 abstract "A dissolution test for milnacipran hydrochloride capsules was developed and validated according to international guidelines. After selection of the best conditions, the method was validated using USP Apparatus 1 (baskets), 50-rpm rotation speed, 900 mL of 0.01 N HCl, and test time of 60 min. The drug released was determined by both LC–UV (PDA) and UV–D methods. The kinetic parameters of drug release (mathematical models, t80%, and dissolution efficiency) were investigated, and the stability of the dosage form was evaluated by analyzing changes in the dissolution rate of milnacipran hydrochloride capsules during storage at 40 °C and 75% RH for different periods. INTRODUCTION Dissolution testing can provide information not only on the rate and extent of drug absorption in the body but also on the effects of drug biopharmaceutical properties and formulation principles on the release properties of a pharmaceutical product (1). Therefore, in vitro dissolution tests are usually used to assess the lot-to-lot quality of a drug product, guide development of new formulations, an d ensure continued product quality and performance after certain changes such as formulation, manufacturing process, site of manufacture, and the scale-up of the manufacturing process (2). The dissolution procedure requires an apparatus, a dissolution medium, and test conditions that provide a method that is discriminating yet sufficiently rugged and reproducible for day-to-day operation and capable of being transferred between laboratories. With regard to stability, the dissolution test should appropriately reflect relevant changes in the drug product caused by temperature, humidity, photosensitivity, and other stresses over time (3). Milnacipran hydrochloride (MNC), [101152-94-7], C15H22N2O⋅HCl, molecular weight 282.81 g/mol (Figure 1), is a racemic mixture with the chemical name (±)-[1R(S),2S(R)]-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride, and its solubility in water is 19 mg/mL (4–6). MNC is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated as an antidepressant and for the management of fibromyalgia. It shows preferential blockade of norepinephrine reuptake over serotonin and minimal activity at other receptors or transporters (6–8). MNC is well absorbed after oral administration with maximum concentrations reached within 2–4 h, and its absorption is not affected by food. It presents an absolute bioavailability of approximately 85–90% (9). The solubility and absolute bioavailability data for this drug classify it as Class I (high solubility and high permeability) based on the Biopharmaceutical Classification System. This is the case where the drug is well absorbed, and for immediate-release dosage forms that dissolve very rapidly, the absorption rate is controlled by the gastric emptying rate, and some correlation with dissolution rate is expected only if the dissolution is slower than gastric emptying (10). Methods for quantitation of milnacipran in combination with other antidepressants and their metabolites in biological fluids have been proposed (11–17). However, there is no compendial method to assay milnacipran hydrochloride in pharmaceutical dosage forms. A stability-indicating liquid chromatographic method with UV detection (LC–UV) and a second-order derivative UV spectroscopic method (UV–D) for quality control of milnacipran in capsules were developed and validated by the authors (18) according to guidelines (19–21). Therefore, the purpose of this work was to develop and validate a dissolution test for MNC in capsules (50 mg) based on its physicochemical characteristics and apply the LC–UV and UV–D methods to quantify the drug released from the capsules during the dissolution procedure. The kinetic parameters of drug release were investigated, and the stability of the dosage form was evaluated by analyzing changes in the dissolution rate of MNC capsules over time and in various storage conditions. EXPERIMENTAL Chemicals Milnacipran hydrochloride was purchased from Synfine Research (Canada). The pharmaceutical dosage form *Corresponding author. diss-18-03-06.indd 47 8/31/2011 1:38:15 PM dx.doi.org/10.14227/DT180311P47" @default.
• W2330367837 created "2016-06-24" @default.
• W2330367837 creator A5022115296 @default.
• W2330367837 creator A5038939972 @default.
• W2330367837 creator A5083070910 @default.
• W2330367837 creator A5091320182 @default.
• W2330367837 date "2011-01-01" @default.
• W2330367837 modified "2023-09-24" @default.
• W2330367837 title "Dissolution Method for Milnacipran Hydrochloride Capsules: Development, Validation, and Study of Changes in Dissolution Rate after Storage" @default.
• W2330367837 cites W1498305210 @default.
• W2330367837 cites W1966960981 @default.
• W2330367837 cites W1990620284 @default.
• W2330367837 cites W1993777943 @default.
• W2330367837 cites W1997956721 @default.
• W2330367837 cites W2016030785 @default.
• W2330367837 cites W2075201570 @default.
• W2330367837 cites W2091003844 @default.
• W2330367837 cites W2092545652 @default.
• W2330367837 cites W2113447800 @default.
• W2330367837 cites W2115439624 @default.
• W2330367837 cites W2412709341 @default.
• W2330367837 cites W580984862 @default.
• W2330367837 doi "https://doi.org/10.14227/dt180311p47" @default.
• W2330367837 hasPublicationYear "2011" @default.
• W2330367837 type Work @default.
• W2330367837 sameAs 2330367837 @default.
• W2330367837 citedByCount "1" @default.
• W2330367837 countsByYear W23303678372013 @default.
• W2330367837 crossrefType "journal-article" @default.
• W2330367837 hasAuthorship W2330367837A5022115296 @default.
• W2330367837 hasAuthorship W2330367837A5038939972 @default.
• W2330367837 hasAuthorship W2330367837A5083070910 @default.
• W2330367837 hasAuthorship W2330367837A5091320182 @default.
• W2330367837 hasBestOaLocation W23303678371 @default.
• W2330367837 hasConcept C14029885 @default.
• W2330367837 hasConcept C170493617 @default.
• W2330367837 hasConcept C178790620 @default.
• W2330367837 hasConcept C185592680 @default.
• W2330367837 hasConcept C2775864247 @default.
• W2330367837 hasConcept C2780199185 @default.
• W2330367837 hasConcept C2781430271 @default.
• W2330367837 hasConcept C43617362 @default.
• W2330367837 hasConcept C55493867 @default.
• W2330367837 hasConcept C88380143 @default.
• W2330367837 hasConceptScore W2330367837C14029885 @default.
• W2330367837 hasConceptScore W2330367837C170493617 @default.
• W2330367837 hasConceptScore W2330367837C178790620 @default.
• W2330367837 hasConceptScore W2330367837C185592680 @default.
• W2330367837 hasConceptScore W2330367837C2775864247 @default.
• W2330367837 hasConceptScore W2330367837C2780199185 @default.
• W2330367837 hasConceptScore W2330367837C2781430271 @default.
• W2330367837 hasConceptScore W2330367837C43617362 @default.
• W2330367837 hasConceptScore W2330367837C55493867 @default.
• W2330367837 hasConceptScore W2330367837C88380143 @default.
• W2330367837 hasIssue "3" @default.
• W2330367837 hasLocation W23303678371 @default.
• W2330367837 hasOpenAccess W2330367837 @default.
• W2330367837 hasPrimaryLocation W23303678371 @default.
• W2330367837 hasRelatedWork W2027516510 @default.
• W2330367837 hasRelatedWork W2092267554 @default.
• W2330367837 hasRelatedWork W2330367837 @default.
• W2330367837 hasRelatedWork W2330572437 @default.
• W2330367837 hasRelatedWork W2349563708 @default.
• W2330367837 hasRelatedWork W2363105180 @default.
• W2330367837 hasRelatedWork W2378892754 @default.
• W2330367837 hasRelatedWork W2384346418 @default.
• W2330367837 hasRelatedWork W2388513130 @default.
• W2330367837 hasRelatedWork W2389643737 @default.
• W2330367837 hasVolume "18" @default.
• W2330367837 isParatext "false" @default.
• W2330367837 isRetracted "false" @default.
• W2330367837 magId "2330367837" @default.
• W2330367837 workType "article" @default.